**Supplementary Figure Legends**

***Supplementary Figure 1: CD47 is expressed in pancreatic cancer (stem) cells.***
(**A**) Representative images of TMA cores of normal pancreas and PDAC tissue stained for CD47. **(B)** Image of a large section of PDAC stained for CD47. (**C**) Kaplan Meier Curves for patients with PDAC dichotomized for CD47 expression as determined by IHC. Neg: no or low; Pos: medium or high CD47 expression. The two Kaplan Meier plots represent two independent study populations.

***Supplementary Figure 2: Macrophage differentation and Anti-CD47 effects in a ratio 1:1 with pancreatic cancer stem cells.*** (**A**) Phagocytic index for unpolarized macrophages and macrophages polarized using different protocols (**left panel**). Western blot analysis showing specific expression of iNOS as M1 marker in macrophages polarized with GM-CSF and IFN/LPS and Arginase as M2 marker in macrophages polarized with M-CSF and IL-4. Utilized antibodies are provided below the blot (**right panel**). (**B**) Representative images (**left panel**) and phagocytic index (**middle panel**) of 185-GFP and 354-GFP cells following treatment with anti-CD47 or iso-control antibody. Phagocytic index for non-transformed cells (Human Pancreatic Ductal Epithelial cells, HPDE, or primary Pancreatic Stellate Cells, PSC) following treatment with anti-CD47 or iso-control antibody (**right panel**) (**C**) Sphere formation capacity after treatment with anti-CD47 or iso-control. (**D**) CD133 expression after treatment with anti-CD47 or iso-control. (**E**) Tumorigenicity at 2 months for cells that survived treatment with Anti-CD47 or iso-control. (**F**) Phagocytic index of 185-GFP and 215-GFP after treatment with anti-CD47, anti-CD44, or iso-control.

***Supplementary Figure 3:*** ***Apoptosis induction after CD47 treatment.*** (**A**) Flow cytometry analysis of apoptosis, determined by Annexin V/DAPI staining, in murine PDAC cells after 12h treatment with anti-CD47 mAbs (B6H12) or IgG1 isotype control Ab and
(**B**) in human PDAC cells after 2 h treatment.

***Supplementary Figure 4: Histological analysis following in vivo treatment.***(**A**)Immunohistochemistry for YM1(macrophage marker) and CD31 (blood vessel marker) in paraffin sections from tumors harvested from the indicated group.
(**B**) Experimental setup for *in vivo* intervention study **(upper panel)** and effects of allocated treatment in 215 tissue xenografts transplanted in immunocompromised mice **(lower panel).** The mean tumor volume (+SD) is indicated; n=6 tumors per group**. (C)** Flow cytometry analysis of CD133+ cells in tumors of mice treated as indicated.